Keith Tolley - Concepedia

Author

Keith Tolley

University of Nottingham ORCID

Also Known As

K Tolley, K. H. Tolley, K. Tolley, KEITH TOLLEY, Keith H Tolley, Keith H. Tolley, Keith Tolley, Tolley K

154

Publications

Citations

H-Index

Concepts

All Affiliations

University of Nottingham Buxton Hospital University of Groningen University College London Ospedale San Bortolo

About

Keith Tolley is an author at University of Nottingham specializing in medicine, public health, and health economics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	22	596
2	Health Sciences	3	3	82
3	Business	2	2	73
4	Nursing	2	2	47
5	Law	1	1	16

Keith Tolley

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
A Network Meta-Analysis of the Relative Efficacy of Treatments for Actinic Keratosis of the Face or Scalp in Europe Stefan Vegter, Keith Tolley PLoS ONE	2014	125
Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia Keith Tolley, Catherine Goad, Yunni Yi, The European Journal of Health Economics Hematological MalignancyUk General PublicHealth EconomicsClinical EffectivenessHealth Policy	2012	86
Cost-Utility Analysis of Primary Prophylaxis versus Treatment On-Demand for Individuals with Severe Haemophilia Alexander H. Miners, Caroline Sabin, Keith Tolley, PharmacoEconomics Preventive MedicineCost-utility AnalysisHealth PolicyHealth EconomicsHealth Care Reimbursement	2002	80
Assessing the effectiveness and cost‐effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease A Miners, Caroline Sabin, Keith Tolley, Journal of Internal Medicine	1998	76
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders Michael Schlander, Silvio Garattini, Søren Holm, Journal of Comparative Effectiveness Research	2014	65
Discounting of Health Benefits in the Pharmacoeconomic Analysis of Drug Therapies Doug Coyle, Keith Tolley PharmacoEconomics Pharmacoeconomic AnalysisEconomicsHealth EconomicsBusinessDrug Therapies	1992	57
Treatment for life for severe haemophilia A– A cost‐utility model for prophylaxis vs. on‐demand treatment Albert Farrugia, Josephine Cassar, Mary Clare Kimber, Haemophilia Preventive MedicineHealthcare ValueHealth EconomicsHealth PolicyCost Utility	2013	56
Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom Jonathan Karnon, Keith Tolley, J Oyee, Current Medical Research and Opinion	2008	48
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective M. Charokopou, Phil McEwan, Steven Lister, BMC Health Services Research	2015	40
8th European Conference on Rare Diseases & Orphan Products (ECRD 2016) Michael Schlander, Søren Holm, Erik Nord, Orphanet Journal of Rare Diseases	2016	39

Page 1